Company news

Moderna, Inc. news in 2022

Moderna, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Moderna Finalizes Strategic Partnership with UK Government

December 20, 2022

Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial

December 19, 2022

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna’s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union

December 15, 2022

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

December 12, 2022

Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

December 7, 2022

Brad Miller Joins Moderna as Chief Information Officer

December 6, 2022

David Jiménez Joins Moderna As U.S. General Manager

November 16, 2022

Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

November 13, 2022

Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster

November 3, 2022

Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 2, 2022

Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries

October 16, 2022

Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022

October 12, 2022

Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age

October 11, 2022

Moderna Creates New Executive Committee Role Ahead of New Product Launches

September 28, 2022

European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine

September 27, 2022

Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Booster Vaccine

August 31, 2022

Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older

August 30, 2022

Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia

August 29, 2022

Moderna to Host R&D Day on Thursday, September 8, 2022

August 28, 2022

Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform

August 25, 2022

Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222

August 22, 2022

Moderna to Supply 12 Million Doses of Omicron-Containing Bivalent COVID-19 Booster Vaccines to the Government of Canada

August 21, 2022

James Mock Joins Moderna as Chief Financial Officer

August 16, 2022

Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses

August 7, 2022

Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates

August 2, 2022

Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses

July 28, 2022

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union

July 21, 2022

Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)

July 13, 2022

Moderna to Report First Quarter Financial Results on Wednesday, August 3, 2022

July 12, 2022

Moderna Announces First Participant Dosed in a Phase 1 Trial of its Nipah Virus mRNA Vaccine, mRNA-1215

July 11, 2022

Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5

June 21, 2022

Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom

June 20, 2022

Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older

June 16, 2022

Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron

June 7, 2022

Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)

June 6, 2022

Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement

June 1, 2022

Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

May 30, 2022

Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day

May 16, 2022

Departure of Jorge Gomez and Continuation of David Meline as Chief Financial Officer

May 10, 2022

Moderna to Host Annual Science and Technology Day on May 17, 2022

May 8, 2022

Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates

May 3, 2022

Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union

April 28, 2022

Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age

April 27, 2022

Arpa Garay Joins Moderna as Chief Commercial Officer

April 26, 2022

Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform

April 18, 2022

Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022

April 12, 2022

Jorge Gomez Joins Moderna as Chief Financial Officer

April 10, 2022

Moderna Launches New Charitable Foundation

April 3, 2022

Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273

March 28, 2022

Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day

March 23, 2022

Older news releases →

Calls in 2022

Decks in 2022